Minai-Azary Jennifer Lynn 4
4 · Context Therapeutics Inc. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
Context Therapeutics CFO Jennifer Minai-Azary Receives 275,000-Share Award
What Happened
Jennifer Minai-Azary, Chief Financial Officer of Context Therapeutics (CNTX), received a grant/award of derivative securities covering 275,000 shares on February 19, 2026. The filing reports an acquisition at $0.00 (reported value $0) — this is a time-based equity award (derivative), not an open-market purchase or sale.
Key Details
- Transaction date: February 19, 2026; Form 4 filed February 23, 2026 (timely).
- Instrument: Derivative award (option/award) for 275,000 shares; reported price/exercise $0.00; reported value $0.
- Vesting (footnote): 25% vests on February 19, 2027; remaining 75% vests in equal monthly installments over the next three years, subject to continued service.
- Shares owned after transaction: Not disclosed in this Form 4.
- No indication in the filing of an immediate sale, tax withholding, 10b5-1 plan, or late filing.
Context
This was a time‑based executive equity award intended to vest over four years (standard for incentive grants). Because it’s a derivative/time-vested award, it does not represent immediately available cash or marketed shares; vested portions would become exercisable according to the schedule. Such grants are common as part of executive compensation and are informational for investors tracking insider alignment with company performance.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-02-19+275,000→ 275,000 totalExercise: $2.32Exp: 2036-02-18→ Common Stock (275,000 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.